Soluble ICAM-1 in CSF coincides with the extent of cerebral damage in patients with severe traumatic brain injury.
about
Adhesion molecules in CNS disorders: biomarker and therapeutic targetsValidation of serum markers for blood-brain barrier disruption in traumatic brain injury.A narrative literature review of depression following traumatic brain injury: prevalence, impact, and management challengesRole of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.Principal component analysis of the cytokine and chemokine response to human traumatic brain injury.Guilty molecules, guilty minds? The conflicting roles of the innate immune response to traumatic brain injuryPrincipal components derived from CSF inflammatory profiles predict outcome in survivors after severe traumatic brain injuryBlood-brain barrier breakdown as a therapeutic target in traumatic brain injury.Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury.Cytokines and brain injury: invited review.Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury.Blood-brain barrier pathophysiology in traumatic brain injury.The role of markers of inflammation in traumatic brain injury.Adhesion molecule levels in serum and cerebrospinal fluid in children with bacterial meningitis and sepsis.Multiplex assessment of serum biomarker concentrations in well-appearing children with inflicted traumatic brain injury.Sialylated complex-type N-glycans enhance the signaling activity of soluble intercellular adhesion molecule-1 in mouse astrocytes.The Serum Changes of Neuron-Specific Enolase and Intercellular Adhesion Molecule-1 in Patients With Diffuse Axonal Injury Following Progesterone Administration: A Randomized Clinical Trial.The Passage of S100B from Brain to Blood Is Not Specifically Related to the Blood-Brain Barrier Integrity.Acute Inflammatory Response Following Increased Blood-Brain Barrier Permeability Induced by Focused Ultrasound is Dependent on Microbubble Dose.Inflammation and immune system activation after traumatic brain injury.Differential disruption of blood-brain barrier in severe traumatic brain injury.
P2860
Q27015967-009A8B87-5993-40BE-BFCC-1DEAA7DA605BQ33657728-12E1BF60-C7F8-4BCE-885C-E91FDB80D12BQ33813083-33DABD2D-6722-462C-B1F1-6573986730B4Q34170906-4AA50049-CDBC-4D8E-A72E-3FAC4623C696Q34321617-77244A0E-AD3C-400B-8862-423D28B5B02FQ36026673-7316CB3E-99FB-4D5B-8E44-B3AE8304A4CFQ36664950-B536A0AA-8E3E-44B6-9431-BFA76E31DCDDQ36763899-13007B35-C8EF-4270-BA50-5A2557CECD61Q37023836-2D3144FC-34E8-4282-886A-69A5D504056FQ37173555-7CE4FCCC-DA55-431A-B92E-6454FB61B9C8Q37374156-1D4365A8-1CA6-413C-9BF0-2B6C69E993E4Q37980746-73A9B996-81F7-4C71-AFD9-2859E078451DQ38086443-D88B1F95-2F7F-4CAD-844B-51B7F2AC4C11Q38265637-538554D9-8A34-43AA-B142-EB8BD498654AQ40048034-367EEA65-56AB-4825-BF1A-68FFB26E74FAQ40544627-E66FA8DF-FC0F-4EC2-BDE9-DB530336E38AQ41572195-5C7A46F5-B52C-437C-A538-384EACCF4CB0Q42008737-02D39031-784B-4A8B-8E77-A60570BB6B8BQ43693994-95DD5CBC-BFB7-4D63-96C0-37CEF039A8B5Q48596103-77D36409-4111-4F4D-A93B-27F8F23E89E3Q48872166-FDDD3822-2FE1-476C-BC20-A1571295CCBD
P2860
Soluble ICAM-1 in CSF coincides with the extent of cerebral damage in patients with severe traumatic brain injury.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Soluble ICAM-1 in CSF coincide ...... severe traumatic brain injury.
@en
Soluble ICAM-1 in CSF coincide ...... severe traumatic brain injury.
@nl
type
label
Soluble ICAM-1 in CSF coincide ...... severe traumatic brain injury.
@en
Soluble ICAM-1 in CSF coincide ...... severe traumatic brain injury.
@nl
prefLabel
Soluble ICAM-1 in CSF coincide ...... severe traumatic brain injury.
@en
Soluble ICAM-1 in CSF coincide ...... severe traumatic brain injury.
@nl
P2093
P356
P1476
Soluble ICAM-1 in CSF coincide ...... severe traumatic brain injury.
@en
P2093
Kossmann T
Morganti-Kossmann MC
Pleines UE
P304
P356
10.1089/NEU.1998.15.399
P577
1998-06-01T00:00:00Z